OTCMSWOBY
Market cap9.66bUSD
Dec 18, Last price
14.20USD
1D
-5.33%
IPO
53.18%
Name
Swedish Orphan Biovitrum AB (publ)
Chart & Performance
Profile
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 22,123,000 17.74% | 18,790,000 21.00% | 15,529,000 1.76% | |||||||
Cost of revenue | 17,952,000 | 14,977,000 | 11,772,000 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 4,171,000 | 3,813,000 | 3,757,000 | |||||||
NOPBT Margin | 18.85% | 20.29% | 24.19% | |||||||
Operating Taxes | 546,000 | 683,000 | 616,000 | |||||||
Tax Rate | 13.09% | 17.91% | 16.40% | |||||||
NOPAT | 3,625,000 | 3,130,000 | 3,141,000 | |||||||
Net income | 2,409,000 -8.68% | 2,638,000 -1.53% | 2,679,000 -17.44% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 6,129,000 | 89,000 | ||||||||
BB yield | -7.04% | -0.13% | ||||||||
Debt | ||||||||||
Debt current | 8,961,000 | 5,929,000 | 1,882,000 | |||||||
Long-term debt | 11,840,000 | 3,505,000 | 9,385,000 | |||||||
Deferred revenue | 234,000 | |||||||||
Other long-term liabilities | 2,861,000 | 4,146,000 | 3,834,000 | |||||||
Net debt | 19,755,000 | 7,952,000 | 10,023,000 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 4,470,000 | 4,665,000 | 5,470,000 | |||||||
CAPEX | (407,000) | (1,477,000) | (370,000) | |||||||
Cash from investing activities | (21,904,000) | (1,477,000) | (367,000) | |||||||
Cash from financing activities | 17,012,000 | (2,991,000) | (4,474,000) | |||||||
FCF | 2,863,000 | 3,281,000 | 3,776,000 | |||||||
Balance | ||||||||||
Cash | 904,000 | 1,361,000 | 1,045,000 | |||||||
Long term investments | 142,000 | 121,000 | 199,000 | |||||||
Excess cash | 542,500 | 467,550 | ||||||||
Stockholders' equity | 17,315,000 | 16,314,000 | 13,324,000 | |||||||
Invested Capital | 57,213,000 | 38,844,500 | 37,405,450 | |||||||
ROIC | 7.55% | 8.21% | 8.37% | |||||||
ROCE | 6.53% | 8.83% | 9.06% | |||||||
EV | ||||||||||
Common stock shares outstanding | 325,968 | 312,455 | 310,729 | |||||||
Price | 267.00 23.78% | 215.70 16.53% | 185.10 11.44% | |||||||
Market cap | 87,033,362 29.14% | 67,396,595 17.18% | 57,515,929 11.12% | |||||||
EV | 106,788,362 | 75,348,595 | 67,604,929 | |||||||
EBITDA | 7,340,000 | 6,232,000 | 5,763,000 | |||||||
EV/EBITDA | 14.55 | 12.09 | 11.73 | |||||||
Interest | 1,111,000 | 458,000 | 419,000 | |||||||
Interest/NOPBT | 26.64% | 12.01% | 11.15% |